Comparative Pharmacology
Head-to-head clinical analysis: CYANOKIT versus PRALIDOXIME CHLORIDE.
Head-to-head clinical analysis: CYANOKIT versus PRALIDOXIME CHLORIDE.
CYANOKIT vs PRALIDOXIME CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin, a form of vitamin B12, acts as a scavenger of cyanide ions by binding with them to form cyanocobalamin, which is then excreted in urine. It has a higher affinity for cyanide than cytochrome c oxidase, thereby restoring mitochondrial function.
Pralidoxime chloride is a cholinesterase reactivator. It reactivates acetylcholinesterase that has been inactivated by phosphorylation due to organophosphate or carbamate exposure by binding to the organophosphate moiety and cleaving the enzyme-phosphate bond, thereby restoring enzymatic activity. It also has direct antimuscarinic and antinicotinic effects at high doses.
5 g intravenous infusion over 15 minutes for adults and pediatric patients weighing >=40 kg. A second dose of 5 g may be administered if needed based on clinical response.
1-2 g IV over 15-30 minutes, may repeat in 1 hour if muscle weakness persists, then every 10-12 hours as needed; typically given with atropine. Maximum dose: 2 g/hour or 12 g/day.
None Documented
None Documented
The terminal elimination half-life of hydroxocobalamin is approximately 24-28 hours in healthy adults; in cyanide poisoning, the half-life may be prolonged due to reversible binding to cyanide.
Terminal elimination half-life is approximately 1.5–2.5 hours in adults. In renal impairment, half-life may be prolonged up to 5–6 hours, necessitating dose adjustment.
Primarily renal elimination as hydroxocobalamin and cyanocobalamin; >90% of an intravenous dose is excreted in urine within 72 hours, with the remainder eliminated in feces via biliary excretion.
Renal: >90% as unchanged drug and metabolites (including pyridone and pyridinium derivatives). Biliary/fecal: <5%.
Category C
Category C
Antidote
Antidote